Drug Database
CL

clopidogrel besylate (Plavid)

✓ Approved

HanAll Biopharma · P2RY12 · Small Molecule

What is clopidogrel besylate?

clopidogrel besylate is a small molecule developed by HanAll Biopharma. It is approved for therapeutic indications via unknown.

Drug Profile

Brand NamesPlavid
CompanyHanAll Biopharma
Drug ClassSmall Molecule
Molecular TargetP2RY12
RouteUnknown
StatusApproved
Sources: ClinicalTrials.gov, HanAll Biopharma

Mechanism of Action

Molecular Targets

clopidogrel besylate acts on 1 molecular target:

P2RY12purinergic receptor P2Y12 (P2Y(ADP), P2Y(cyc))
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

clopidogrel besylate is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Vascular disordersThrombosis✓ Approved

Related Research Articles

PubMedLuminescence : the journal of biological and chemical luminescence2026-08-24

Micellar Enhanced Second Derivative Spectrofluorimetric Determination of Hydrochlorothiazide, Amlodipine, and Telmisartan in Fixed Dose Combination and Spiked Human Plasma.

Yenduri Suvarna S, H Shashank S, K Naga Prashant NP

A very sensitive and eco-friendly second-derivative spectrofluorimetric method was developed for simultaneous analysis of hydrochlorothiazide (HCTZ), amlodipine besylate (AML), and telmisartan (TEL) in pharmaceutical products and human plasma. Native fluorescence of HCTZ (λex267/λem295 nm), AML (λex362/λem415 nm), and TEL (λex292/λem369 nm) was used together with fluorescence enhancement achieved through sodium lauryl sulfate micelles at optimum excitation/emission wavelengths for all other analytes being analyzed. Overlap of spectroscopic data was able to be resolved through second-derivative spectrofluorimetry without prior separation. Method validation was performed according to ICH Q2(R1) guidelines; results showed excellent linearity (R2 > 0.999) across a concentration range of 3-18, 2-10, and 10-50 ng/mL for HCTZ, AML, and TEL, respectively. Accuracy, precision and robustness were demonstrated with %RSD values below two. Application of the method to pharmaceutical product and spiked plasma samples gave satisfactory recoveries with minimal matrix interference. Assessment of method greenness was conducted using AGREE Prep, MoGAPI, AGSA, SAMI, Ma Tool, CACI, and WECA metrics, all of which indicate superior environmental sustainability. The proposed method is simple, fast, low-cost, ultra-sensitive, and suitable for routine quality control and/or bioanalytical analysis.

PMID 42634090
Read full article →
PubMedCureus2026-08-21

Therapeutic Dilemma in Epidural Catheter Removal During Dual Antiplatelet Therapy and Anticoagulation Following Hepatic Artery Injury: A Case Report.

Lousada Talita Larissa de Castro TLC, Ferreira Ana Paula de Souza Barbosa APSB, Dorna Bruno Eduardo Silva BES, Raso Lucas Augusto Carvalho E LACE

Epidural catheter removal in the setting of concurrent dual antiplatelet therapy (DAPT) and anticoagulation poses a high risk of neuraxial hematoma. Current guidelines mandate prolonged interruption of antithrombotic therapy, which may be unfeasible in patients with recently implanted arterial stents at high risk of thrombosis. We present the case of a 56-year-old man who underwent combined epidural and general anesthesia for a partial hepatectomy. An inadvertent intraoperative injury to the proper hepatic artery required aborting the surgery and deployment of a rescue drug-eluting stent. Intravenous unfractionated heparin and DAPT (aspirin and clopidogrel) were initiated. On postoperative day 7, inflammatory signs at the epidural catheter site made its removal urgent. However, interrupting clopidogrel for the guideline-recommended five to seven days posed an unacceptable risk of acute thrombosis of the newly deployed hepatic artery stent. To navigate this conflict between preventing neuraxial hematoma and acute hepatic ischemia, a multidisciplinary team reached a consensus to implement an unorthodox 24-hour therapeutic window off antithrombotics. The catheter was removed uneventfully at the end of this period; antiplatelet therapy and enoxaparin were restarted at two and six hours, respectively. No neurological deficits occurred. This case illustrates that, in scenarios of competing high-risk priorities, strict adherence to standardized recommendations may not be feasible. An individualized strategy based on multidisciplinary consensus, careful timing of antithrombotic interruption and reintroduction, and close neurological monitoring was successfully implemented without complications in this patient. However, given the limitations of a single case report, this individualized salvage strategy should not be generalized and requires further clinical evidence.

PMID 42626692
Read full article →
PubMedJournal of neuroendovascular therapy2026-08-21

An Uninterrupted DOAC plus Single Antiplatelet Strategy for Carotid Artery Stenting in Patients with Atrial Fibrillation.

Suzuki Koichiro K, Horio Yoshinobu Y, Inoue Ritsuro R, Wakuta Naoki N et al.

Periprocedural antithrombotic management in patients with non-valvular atrial fibrillation (NVAF) undergoing carotid artery stenting (CAS) remains controversial. Although dual antiplatelet therapy is the standard regimen for CAS, its combination with a direct oral anticoagulant (DOAC) as triple therapy increases bleeding risk. On the other hand, interruption of DOAC therapy may increase thromboembolic risk. We evaluated the clinical outcomes and feasibility of an uninterrupted dual antithrombotic therapy (DAT) strategy consisting of a DOAC and single antiplatelet therapy (SAPT). We retrospectively reviewed a case series of 10 patients with NVAF treated between 2018 and 2025 who underwent CAS while continuing DOAC plus SAPT without interruption. In all cases, SAPT (clopidogrel, aspirin, or prasugrel) was initiated at least 2 weeks before the procedure. Platelet function was assessed using the VerifyNow system (Werfen, Bedford, MA, USA). We evaluated baseline clinical characteristics, antithrombotic regimens, platelet reactivity, procedural details, and periprocedural clinical outcomes. The mean CHA2DS2-VASc and HAS-BLED scores were 4.4 ± 1.4 and 3.8 ± 1.0, respectively. CAS was successfully performed in all patients. One patient with elevated P2Y12 reaction units required the temporary periprocedural addition of cilostazol. No periprocedural hemorrhagic or thromboembolic complications occurred during the periprocedural period or within 3 months after CAS. Uninterrupted DAT with a DOAC and SAPT may be a feasible periprocedural management strategy for CAS in patients with NVAF, without the need for DOAC interruption or triple therapy.

PMID 42625891
Read full article →
PubMedClinical pharmacology in drug development2026-08-20

Assessment of Pharmacokinetic Interaction and Clinical Efficacy of Clopidogrel Co-administered with Ilaprazole.

N Damodharan D, A Priyadharshini P, T M Vijayakumar V, N A Rajesh R

Clopidogrel is often co-prescribed with proton pump inhibitors (PPIs) to reduce gastrointestinal bleeding risk. However, some PPIs, especially pantoprazole, inhibit CYP2C19, potentially reducing clopidogrel's activation. Ilaprazole, a newer PPI primarily metabolized via CYP3A4, may offer reduced interaction. The study was an open-label, randomized trial that involved 36 healthy male volunteers, who were divided into three groups (n = 12 each): Group 1 (Clopidogrel + Placebo), Group 2 (Clopidogrel + Pantoprazole 40 mg), and Group 3 (Clopidogrel + Ilaprazole 10 mg). After 7 days of treatment, all participants received clopidogrel 75 mg on Day 8. Pharmacokinetic (PK) parameters were analyzed using LC-MS/MS and platelet aggregation by light transmission aggregometry at 0, 4, 10, and 24 h. Pantoprazole significantly reduced clopidogrel AUC (1.96 ± 0.20 vs 8.27 ± 1.04 ng·h/mL, P < .0005), Cmax (0.76 ± 0.04 vs 2.6 ± 1.01 ng/mL, P = .0136), and t1/2 (1.72 ± 0.11 vs 2.22 ± 0.17 h, P = .0312), indicating reduced bioavailability. Geometric mean ratio (GMR) analysis showed a marked reduction in clopidogrel exposure with pantoprazole (Cmax GMR 0.31, 90% CI 0.18-0.53; AUC GMR 0.24, 90% CI 0.19-0.29), and platelet aggregation was significantly higher at 4 and 10 h (P < .05). In contrast, ilaprazole preserved PK parameters (AUC 10.18 ± 1.41, Cmax 3.06 ± 1.05), GMRs near unity (Cmax 1.20, 90% CI 0.60-2.42; AUC 1.23, 90% CI 0.97-1.55), indicating no inhibitory effect and platelet inhibition comparable to placebo (P > .05) Ilaprazole did not affect clopidogrel pharmacokinetics or pharmacodynamics, suggesting it as a safer alternative to pantoprazole in dual antiplatelet therapy.

PMID 42622073
Read full article →
PubMedJournal of the American Heart Association2026-08-20

Clopidogrel Versus Dual-Antiplatelet Therapy for Long-Term Maintenance After Coronary Stenting in Ischemic and Bleeding Birisk Patients With Acute Coronary Syndromes and Diabetes: A Prespecified Subgroup Analysis of the OPT-BIRISK Trial.

Zhang Dali D, Li Yi Y, Qiu Miaohan M, Zhou Yujie Y et al.

Among patients with acute coronary syndromes at both high bleeding and ischemic risk (birisk), extended clopidogrel monotherapy after 9 to 12 months of dual-antiplatelet therapy reduces bleeding without increasing ischemia. Whether this benefit extends to birisk patients with diabetes is unknown. This prespecified subgroup analysis of the OPT-BIRISK (Optimal Antiplatelet Therapy for High Bleeding and Ischemic Risk Patients) trial included birisk patients with acute coronary syndrome who had completed 9 to 12 months of dual-antiplatelet therapy after percutaneous coronary intervention. Patients were then randomized 1:1 to 9 months of clopidogrel plus placebo versus clopidogrel plus aspirin. Outcomes were compared by diabetes status. The primary end point was Bleeding Academic Research Consortium type 2, 3, or 5 bleeding at 9 months after randomization. The key secondary end point was major adverse cardiac and cerebral events, defined as a composite outcome of all-cause death, myocardial infarction, stroke, or clinically driven revascularization. Of 7758 patients, 4072 (52.5%) had diabetes. Clopidogrel monotherapy decreased Bleeding Academic Research Consortium type 2, 3, or 5 bleeding (2.1% versus 3.2%; hazard ratio [HR], 0.66 [95% CI, 0.45-0.97]) with no increase in major adverse cardiac and cerebral events (2.9% versus 3.6%; HR, 0.79 [95% CI, 0.56-1.12]) compared with clopidogrel plus aspirin in patients with diabetes. Outcomes were consistent in patients without diabetes, with no significant interactions by diabetes status. In birisk patients with acute coronary syndrome who were stable on dual-antiplatelet therapy with clopidogrel plus aspirin for 9 to 12 months after percutaneous coronary intervention, clopidogrel monotherapy for an additional 9 months reduced clinically relevant bleeding without increasing ischemic events compared with continued dual-antiplatelet therapy, irrespective of diabetes status. URL: https://clinicaltrials.gov; Unique identifier: NCT03431142.

PMID 42622213
Read full article →
PubMedCase reports in pathology2026-08-20

Mass-Forming NSAID-Associated Colopathy Mimicking Right-Sided Colon Cancer: A Case Report.

Yu Hong H, Italiya Sonalben L SL, Wang Hongbo H, Koshy Jason J et al.

Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause mucosal injury throughout the gastrointestinal tract, yet NSAID-related colonic damage remains underrecognized. We report a rare case of an ulcerated colonic mass mimicking carcinoma in a patient with long-term NSAID exposure. The patient, a 63-year-old man with a history of coronary artery disease and coronary artery bypass grafting more than 25 years earlier, was receiving long-term dual antiplatelet therapy consisting of aspirin (81 mg daily) and clopidogrel (75 mg daily), as well as chronic pantoprazole therapy. He presented with a 4-day history of hematochezia without weight loss. Esophagogastroduodenoscopy revealed no bleeding source, but colonoscopy identified an ulcerated, nonobstructive mass in the cecum and proximal ascending colon. A biopsy revealed colonic mucosa with severe ulceration and granulation tissue. The subsequent right hemicolectomy specimen revealed a 5.5-cm, ill-defined ulcerative mass in the cecum and ascending colon. Microscopically, the cecum and ascending colon showed ulcerated mucosa with fibrosis, reactive changes, and foreign body material deposition, without evidence of malignancy. Immunohistochemical stains for cytomegalovirus (CMV) and herpes simplex virus (HSV) were negative. Following surgery, aspirin and clopidogrel were resumed because of the patient's cardiovascular risk. Approximately 1 year later, his hemoglobin level was 12.0 g/dL (6.7 g/dL before surgery), and no gastrointestinal bleeding, diarrhea, or abdominal pain was documented during that encounter. Because aspirin was continued, a clinical response to medication withdrawal could not be assessed. Based on the medication history, right-sided distribution, and histologic findings, the lesion was considered most consistent with suspected aspirin-associated colopathy presenting as a mass-like lesion. However, the concomitant clopidogrel and pantoprazole use and the absence of a formal aspirin dechallenge limited definitive causal attribution.

PMID 42621983
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about clopidogrel besylate